Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group - PubMed (original) (raw)
Clinical Trial
. 1998 Jun 13;351(9118):1755-62.
doi: 10.1016/s0140-6736(98)04311-6.
Affiliations
- PMID: 9635947
- DOI: 10.1016/s0140-6736(98)04311-6
Clinical Trial
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
L Hansson et al. Lancet. 1998.
Abstract
Background: Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension.
Methods: 18790 patients, from 26 countries, aged 50-80 years (mean 61.5 years) with hypertension and diastolic blood pressure between 100 mm Hg and 115 mm Hg (mean 105 mm Hg) were randomly assigned a target diastolic blood pressure. 6264 patients were allocated to the target pressure < or =90 mm Hg, 6264 to < or =85 mm Hg, and 6262 to < or =80 mm Hg. Felodipine was given as baseline therapy with the addition of other agents, according to a five-step regimen. In addition, 9399 patients were randomly assigned 75 mg/day acetylsalicylic acid (Bamycor, Astra) and 9391 patients were assigned placebo.
Findings: Diastolic blood pressure was reduced by 20.3 mm Hg, 22.3 mm Hg, and 24.3 mm Hg, in the < or =90 mm Hg, < or =85 mm Hg, and < or =80 mm Hg target groups, respectively. The lowest incidence of major cardiovascular events occurred at a mean achieved diastolic blood pressure of 82.6 mm Hg; the lowest risk of cardiovascular mortality occurred at 86.5 mm Hg. Further reduction below these blood pressures was safe. In patients with diabetes mellitus there was a 51% reduction in major cardiovascular events in target group < or =80 mm Hg compared with target group < or =90 mm Hg (p for trend=0.005). Acetylsalicylic acid reduced major cardiovascular events by 15% (p=0.03) and all myocardial infarction by 36% (p=0.002), with no effect on stroke. There were seven fatal bleeds in the acetylsalicylic acid group and eight in the placebo group, and 129 versus 70 non-fatal major bleeds in the two groups, respectively (p<0.001).
Interpretation: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events. The HOT Study shows the benefits of lowering the diastolic blood pressure down to 82.6 mm Hg. Acetylsalicylic acid significantly reduced major cardiovascular events with the greatest benefit seen in all myocardial infarction. There was no effect on the incidence of stroke or fatal bleeds, but non-fatal major bleeds were twice as common.
Comment in
- J-curve not burned off by HOT study. Hypertension Optimal Treatment.
Kaplan N. Kaplan N. Lancet. 1998 Jun 13;351(9118):1748-9. doi: 10.1016/s0140-6736(98)22024-1. Lancet. 1998. PMID: 9635941 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Simon A, Levenson J. Simon A, et al. Lancet. 1998 Aug 15;352(9127):571; author reply 574-5. doi: 10.1016/S0140-6736(98)26033-8. Lancet. 1998. PMID: 9716078 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Avanzini F, Marchioli R, Alli C, Tognoni G. Avanzini F, et al. Lancet. 1998 Aug 15;352(9127):571-2; author reply 574-5. doi: 10.1016/S0140-6736(05)79277-1. Lancet. 1998. PMID: 9716079 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Grossman E, Goldbourt U. Grossman E, et al. Lancet. 1998 Aug 15;352(9127):572; author reply 574-5. doi: 10.1016/S0140-6736(05)79278-3. Lancet. 1998. PMID: 9716080 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Gueyffier F, Boissel JP. Gueyffier F, et al. Lancet. 1998 Aug 15;352(9127):572-3; author reply 574-5. doi: 10.1016/S0140-6736(05)79279-5. Lancet. 1998. PMID: 9716081 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Senderovitz T, Kampmann JP. Senderovitz T, et al. Lancet. 1998 Aug 15;352(9127):573; author reply 574-5. doi: 10.1016/S0140-6736(05)79280-1. Lancet. 1998. PMID: 9716082 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Safar ME, Blacher J, Staessen JA. Safar ME, et al. Lancet. 1998 Aug 15;352(9127):573; author reply 574-5. doi: 10.1016/S0140-6736(05)79281-3. Lancet. 1998. PMID: 9716083 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Cruickshank JM. Cruickshank JM. Lancet. 1998 Aug 15;352(9127):573-4; author reply 574-5. doi: 10.1016/s0140-6736(05)79282-5. Lancet. 1998. PMID: 9716084 No abstract available. - Hypertension Optimal Treatment (HOT) trial.
Parving HH. Parving HH. Lancet. 1998 Aug 15;352(9127):574-5. doi: 10.1016/S0140-6736(05)79283-7. Lancet. 1998. PMID: 9716085 No abstract available. - Risk of major gastrointestinal bleeding with aspirin.
Isles C, Norrie J, Paterson J, Ritchie L. Isles C, et al. Lancet. 1999 Jan 9;353(9147):148-50. doi: 10.1016/S0140-6736(05)76185-7. Lancet. 1999. PMID: 10023923 Clinical Trial. No abstract available. - Aspirin, myocardial infarction, and gastrointestinal bleeding.
Cleland JG, Alamgir F. Cleland JG, et al. Lancet. 1999 Feb 20;353(9153):676. doi: 10.1016/s0140-6736(05)75475-1. Lancet. 1999. PMID: 10030365 No abstract available. - What does STOP-2 tell us about management of hypertension?
Siebenhofer A, Zweiker R, Brunner GA, Mrak P, Pieber TR. Siebenhofer A, et al. Lancet. 2000 Feb 19;355(9204):652; author reply 653. doi: 10.1016/S0140-6736(05)72387-4. Lancet. 2000. PMID: 10697002 No abstract available. - First-line antihypertensive therapy.
Hansson L. Hansson L. Lancet. 2000 Aug 5;356(9228):508-9. doi: 10.1016/S0140-6736(05)74179-9. Lancet. 2000. PMID: 10981915 No abstract available.
Similar articles
- The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L. Hansson L. J Hypertens Suppl. 1999 Feb;17(1):S9-13. J Hypertens Suppl. 1999. PMID: 10340838 Clinical Trial. - Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. Kjeldsen SE, et al. J Hypertens. 2000 May;18(5):629-42. doi: 10.1097/00004872-200018050-00017. J Hypertens. 2000. PMID: 10826567 Clinical Trial. - The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability.
Hansson L, Zanchetti A. Hansson L, et al. Blood Press. 1997 Sep;6(5):313-7. doi: 10.3109/08037059709062088. Blood Press. 1997. PMID: 9360003 Clinical Trial. - Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Xie X, et al. Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Epub 2015 Nov 7. Lancet. 2016. PMID: 26559744 Review. - Target Blood Pressure in Patients with Diabetes: Asian Perspective.
Park S, Kario K, Park CG, Huang QF, Cheng HM, Hoshide S, Wang JG, Chen CH; Characteristics On the ManagEment of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG). Park S, et al. Yonsei Med J. 2016 Nov;57(6):1307-11. doi: 10.3349/ymj.2016.57.6.1307. Yonsei Med J. 2016. PMID: 27593856 Free PMC article. Review.
Cited by
- Blood pressure targets for hypertension in people with chronic renal disease.
Erviti J, Saiz LC, Leache L, Pijoan JI, Menéndez Orenga M, Salzwedel DM, Méndez-López I. Erviti J, et al. Cochrane Database Syst Rev. 2024 Oct 15;10(10):CD008564. doi: 10.1002/14651858.CD008564.pub3. Cochrane Database Syst Rev. 2024. PMID: 39403990 Review. - Digital Twin in Managing Hypertension Among People With Type 2 Diabetes: 1-Year Randomized Controlled Trial.
Shamanna P, Joshi S, Dharmalingam M, Vadavi A, Keshavamurthy A, Shah L, Samajdar SS, Mechanick JI. Shamanna P, et al. JACC Adv. 2024 Aug 14;3(9):101172. doi: 10.1016/j.jacadv.2024.101172. eCollection 2024 Sep. JACC Adv. 2024. PMID: 39372467 Free PMC article. - Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis.
Kastrati L, Raeisi-Dehkordi H, Llanaj E, Quezada-Pinedo HG, Khatami F, Ahanchi NS, Llane A, Meçani R, Muka T, Ioannidis JPA. Kastrati L, et al. JAMA Netw Open. 2024 Sep 3;7(9):e2432296. doi: 10.1001/jamanetworkopen.2024.32296. JAMA Netw Open. 2024. PMID: 39240561 Free PMC article. - 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.
Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, Seo JA, Kim MK, Lim JH, Song YJ, Yang YS, Kim JH, Lee YB, Noh J, Hur KY, Park JS, Rhee SY, Kim HJ, Kim HM, Ko JH, Kim NH, Kim CH, Ahn J, Oh TJ, Kim SK, Kim J, Han E, Jin SM, Bae J, Jeon E, Kim JM, Kang SM, Park JH, Yun JS, Cha BS, Moon MK, Lee BW. Moon JS, et al. Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available. - Aspirin in Primary Prevention: Looking for Those Who Enjoy It.
Della Bona R, Giubilato S, Palmieri M, Benenati S, Rossini R, Di Fusco SA, Novarese F, Mascia G, Gasparetto N, Di Monaco A, Gatto L, Zilio F, Sorini Dini C, Borrello F, Geraci G, Riccio C, De Luca L, Colivicchi F, Grimaldi M, Giulizia MM, Porto I, Oliva FG. Della Bona R, et al. J Clin Med. 2024 Jul 16;13(14):4148. doi: 10.3390/jcm13144148. J Clin Med. 2024. PMID: 39064188 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical